Navigation Links
Scientific Data Relating to Cinryze(TM) Presented at 6th Annual C1 Inhibitor Deficiency Workshop
Date:5/26/2009

BUDAPEST, Hungary and EXTON, Pa., May 26 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced the presentation of five abstracts relating to Cinryze(TM) (C1 esterase inhibitor [human]) therapy at the 6th Annual C1 Inhibitor Deficiency Workshop.

Cinryze was approved by the U.S. Food and Drug Administration in October 2008 for routine prophylaxis against hereditary angioedema (HAE) attacks in adults and adolescents. In February 2009, ViroPharma was granted priority review of a supplemental Biologics License Application for Cinryze for the treatment of acute attacks of HAE. If approved, Cinryze would be the first C1 esterase inhibitor available for the acute treatment for this condition. ViroPharma's PDUFA date for Cinryze in the acute setting is June 3, 2009.

"With the C1 Inhibitor Deficiency Workshop presentations focusing on items including HAE treatment considerations and the potential for subcutaneous infusion, among others, ViroPharma is demonstrating our commitment to meeting the needs of patients with C1 deficiency diseases today, and tomorrow," commented Glenn Tillotson, ViroPharma's senior director and head of Medical Affairs.

The following abstracts from studies supported by Lev Pharmaceuticals, a company acquired by ViroPharma Incorporated in October 2008, were presented:

Abstract book page 27: Prophylactic Therapy Considerations in Hereditary Angioedema

  • In an abstract entitled, 'When Should Prophylactic Therapy be Considered for Hereditary Angioedema?', Dr. Tim Craig, et al. described how a literature review, guideline analysis from other countries, expert panel meeting, and consensus development were conducted in order to develop therapy considerations for prophylaxis of HAE in the U.S.;
  • The
    '/>"/>

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Boston Scientific Welcomes Results of Brain Aneurysm Clinical Trial
2. Boston Scientific Begins Clinical Trial for Next-Generation Nitinol Stent to Treat Iliac Artery Disease
3. Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent
4. Boston Scientific Data Show Real-World Survival Rates for Implantable Cardiac Device Patients Exceed Rates From Clinical Trials
5. Journal of American College of Cardiology Article Reports Fewer Repeat Procedures With Boston Scientifics TAXUS(R) Liberte(R) Stent
6. Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine
7. Clinical Data Reinforce Safety and Efficacy of Boston Scientifics Two Drug- Eluting Stent Platforms
8. Results From Efficacy and Safety Study of Cortheras Relaxin in Acute Heart Failure to be Presented at Late-Breaking Clinical Trials Session at ACC 58th Annual Scientific Session
9. New England Journal of Medicine Publishes Results from Boston Scientifics Landmark SYNTAX(TM) Trial
10. Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents
11. Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... , October 31, 2014 ... clinical-stage pharmaceutical company focused on the development of ... will host a conference call to discuss the ... of ORMD-0801, the company,s proprietary oral insulin capsules, ... 3, 2014 at 10:00 a.m. Eastern time. ...
(Date:10/31/2014)... October 31, 2014 Investor-Edge has ... NSPH ), Isis Pharmaceuticals Inc. (NASDAQ: ... HALO ), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ... on these five companies can be accessed at: ... the NASDAQ Composite ended at 4,566.14, up 0.37%, the ...
(Date:10/31/2014)... California , November 3, 2014 ... need for men with BPH to discuss "male orgasmic ... system shows ability to treat prostate symptoms while preserving ... Inc., today welcomes the publication of a paper in ... men suffering from enlarged prostate to discuss with their ...
Breaking Medicine Technology:Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 2Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 3Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 4Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 5Sexual Dysfunction No Longer Inevitable When Treating Enlarged Prostate 2
... (NYSE: LLY ) announced Phase I data on ... (BAFF), for use in combination with bortezomib in patients with ... be presented on Sunday, June 5 at 11:30 a.m. CDT ... (Abstract #8012) at the 47th Annual Meeting of the American ...
... May 19, 2011 Perceptive Informatics , the ... PAREXEL International Corporation (NASDAQ: PRXL ), today ... webinar entitled "Critical Tasks of Site Monitors: Using a ... industry professionals across a broad range of clinical, data ...
Cached Medicine Technology:Study Determined Best Dose and Showed 55 Percent Response Rate With Lilly Anti-BAFF Monoclonal Antibody in Previously-Treated Multiple Myeloma Patients 2Study Determined Best Dose and Showed 55 Percent Response Rate With Lilly Anti-BAFF Monoclonal Antibody in Previously-Treated Multiple Myeloma Patients 3Study Determined Best Dose and Showed 55 Percent Response Rate With Lilly Anti-BAFF Monoclonal Antibody in Previously-Treated Multiple Myeloma Patients 4Perceptive Informatics® Global Survey Results Indicate Growing Demand for CTMS to Assist in More Efficient Site Monitoring and Management 2Perceptive Informatics® Global Survey Results Indicate Growing Demand for CTMS to Assist in More Efficient Site Monitoring and Management 3Perceptive Informatics® Global Survey Results Indicate Growing Demand for CTMS to Assist in More Efficient Site Monitoring and Management 4Perceptive Informatics® Global Survey Results Indicate Growing Demand for CTMS to Assist in More Efficient Site Monitoring and Management 5
(Date:10/31/2014)... 2014 Monica Williams-Murphy MD , ... too well the chaos that can occur for people ... vast majority of Americans who come into the emergency ... completely unprepared for the moment and so are their ... serve as a catalyst for a family to get ...
(Date:10/31/2014)... (PRWEB) October 31, 2014 Energy Textiles ... gear. The new gear is now available online, and ... the benefits of Celliant infrared-active athletic gear over compression ... that another contract has been signed for Under Armour ... for the next eight years. In light of this ...
(Date:10/31/2014)... insomnia is a major contributor to deaths caused by ... results underscore the importance of the "Sleep Well, Be ... , Results show that the risk of unintentional fatal ... of insomnia symptoms present. People with all three symptoms ... from a fatal injury than those with no insomnia ...
(Date:10/31/2014)... North Shore Eye Care today announced the ... and the addition of leading ophthalmologist, William S. Kasper, ... Shore Eye Care Medical Director, Jeffrey Martin, MD. , ... Department of Ophthalmology of Winthrop-University Hospital and has maintained ... more than 30 years. He has been named to ...
(Date:10/31/2014)... 2014 In an effort to expand services ... Jamali announced he will soon offer orthodontics at his Oral ... of November. , To build upon the high degree ... York has become known for, Dr. Jamali is welcoming an ... top learning institutions as UCLA, Stanford and UCSF. He added ...
Breaking Medicine News(10 mins):Health News:This Thanksgiving or Christmas Family Gathering, Use The New App ListStuffFast to Start "The Conversation" With a Parent That Has No Plan For End-of-Life 2Health News:This Thanksgiving or Christmas Family Gathering, Use The New App ListStuffFast to Start "The Conversation" With a Parent That Has No Plan For End-of-Life 3Health News:Compression Gear--Is There a Better Alternative? 2Health News:Compression Gear--Is There a Better Alternative? 3Health News:Compression Gear--Is There a Better Alternative? 4Health News:Insomnia increases risk of motor vehicle deaths, other fatal injuries 2Health News:William Kasper, MD Garden City Ophthalmologist, Joins Medical Staff at North Shore Eye Care 2Health News:William Kasper, MD Garden City Ophthalmologist, Joins Medical Staff at North Shore Eye Care 3Health News:Oral & Maxillofacial Surgery of New York Adds Orthodontic Patient Services 2Health News:Oral & Maxillofacial Surgery of New York Adds Orthodontic Patient Services 3
... Nov. 14 For the sixth consecutive,year, VSP Vision ... World Class Customer Satisfaction Award from Service Quality,Measurement Group, ... in the past two years,we have added over two ... President of Customer Service Laura Costa. "We also had ...
... Through the implementation,of its best management practices (BMPs), ... protecting the environment, the ADA told Congress today., ... have had a very positive,impact," said Dr. J. ... the House Oversight and Government Reform Committee,s,domestic policy ...
... key mechanism in how bacteria communicate with each other, a ... other bacterial diseases. , The mechanism is a chemical ... known as CAI-1, and has been isolated in the lab ... the chemical also can be used to disrupt the communication ...
... Grill & Bar, other partners and donors share ... into the new National,Pediatric Brain Tumor Consortium headquarters, ... learning in,translational research for exceptional patient care, ... Hospital(R) and Chili,s Grill & Bar(R) celebrated the ...
... Nov. 14 Transcept,Pharmaceuticals, Inc. today announced that ... Officer, will present at the 19th Annual,Piper Jaffray ... New York City,on Tuesday, November 27, 2007 at ... Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical ...
... 50-State Disability Rights Bus Tour and Traveling Exhibit,Returns ... Senator Tom Harkin and,other members of Congress will ... back The Road To Freedom: Keeping the Promise ... cross-country bus tour,and traveling exhibit promoting the civil ...
Cached Medicine News:Health News:VSP Vision Care Recognized for World Class Customer Satisfaction 2Health News:ADA Outlines Successful Environmental Efforts 2Health News:Princeton scientists break cholera's lines of communication 2Health News:Princeton scientists break cholera's lines of communication 3Health News:St. Jude Celebrates Next Frontier of Finding Cures With Grand Opening of Chili's Care Center 2Health News:St. Jude Celebrates Next Frontier of Finding Cures With Grand Opening of Chili's Care Center 3Health News:St. Jude Celebrates Next Frontier of Finding Cures With Grand Opening of Chili's Care Center 4Health News:Members of Congress and Disability Rights Advocates Support the Restoration of the Americans with Disabilities Act and Welcome Back the Road To Freedom Bus 2Health News:Members of Congress and Disability Rights Advocates Support the Restoration of the Americans with Disabilities Act and Welcome Back the Road To Freedom Bus 3
... refrigerated floor-standing centrifuge. Mobile space saver, ... choice of accessories, analog controls, large ... shutdown (JOUAN patented pendulum system), guard ... temperature limitation, rugged motor, tough steel ...
... refrigerated bench-top centrifuge. Very ... large choice of accessories, ... true sample temperature control, ... true RCF, informative display, ...
Powerful refrigerated bench-top centrifuge. Very powerful, high capacity rotors, large choice of accessories, heat labile sample protection, guard barrier, dual lid interlock, easy to use, variable c...
GP8RF is a powerful 3-liter ventilated centrifuge which is flexible, easy to use and fit on, beside or below the lab bench. Performs separations 50-100% faster than the rest, powerful, accommodating ...
Medicine Products: